Tau activation of microglial cGAS–IFN reduces MEF2C-mediated cognitive resilience

Pathological hallmarks of Alzheimer’s disease (AD) precede clinical symptoms by years, indicating a period of cognitive resilience before the onset of dementia. Here, we report that activation of cyclic GMP–AMP synthase (cGAS) diminishes cognitive resilience by decreasing the neuronal transcriptional network of myocyte enhancer factor 2c (MEF2C) through type I interferon (IFN-I) signaling. Pathogenic tau activates cGAS and IFN-I responses in microglia, in part mediated by cytosolic leakage of mitochondrial DNA. Genetic ablation of Cgas in mice with tauopathy diminished the microglial IFN-I response, preserved synapse integrity and plasticity and protected against cognitive impairment without affecting the pathogenic tau load. cGAS ablation increased, while activation of IFN-I decreased, the neuronal MEF2C expression network linked to cognitive resilience in AD. Pharmacological inhibition of cGAS in mice with tauopathy enhanced the neuronal MEF2C transcriptional network and restored synaptic integrity, plasticity and memory, supporting the therapeutic potential of targeting the cGAS–IFN–MEF2C axis to improve resilience against AD-related pathological insults.

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated Our web collection on statistics for biologists contains articles on many of the points above.

Software and code
Policy information about availability of computer code Data collection No software was used to collect data.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

March 2021
Data Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: -Accession codes, unique identifiers, or web links for publicly available datasets -A description of any restrictions on data availability -For clinical datasets or third party data, please ensure that the statement adheres to our policy All data associated with this study are in the paper or the Supplementary materials. All RNA-seq data have been deposited to the Gene Expression Omnibus (GEO) under accession number GSE226385. Unedited and uncropped scans of all blots are supplied in the source data files.

Human research participants
Policy information about studies involving human research participants and Sex and Gender in Research.

Reporting on sex and gender
De-identified human postmortem brain samples were obtained from UCSD and Mount Sinai NIH Brain and Tissue Repository. Samples from male (n=6) and female (n=12) subjects were used in the study. The gender information for each sample is reported in the supplementary table 3.

Population characteristics
The information for age, Braak stage and clinical diagnosis and postmortem interval (PMI) is provided for all human brain samples in supplementary table 3.

Recruitment
The participants were recruited in accordance with the above-mentioned Biobank recruitment strategies. For the current study, the brain samples were chosen based on Braak stage (0, 1 or 6).

Ethics oversight
The collection and banking of the samples were carried out in accordance with the Institutional Review Board (IRB) protocols for the respective Brain banks.
Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting
Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design
All studies must disclose on these points even when the disclosure is negative.

Sample size
The sample size for in vivo and in vitro experiments was determined on the basis of previous publications and our experience. For the studies in live animals, the number of animals was determined by power analysis using information from similar studies published by our group or others. For studies involving brain section analyses, the number of slices was determined based on our previous studies to account for variabilities. For in vitro experiments, we determined the experimental replications to account for the technical variabilities and changes with treatment based on our experience. No statistical methods were used to predetermine sample sizes but our sample sizes are similar to those reported in previous publications (PMID: 35413950, PMID: 34851693).

Replication
All in vitro experiments were performed with a minimum of 3 biological replicates. All in vivo experiments involving behavioral tests and pathology analysis were performed with a minimum of 4 mice per genotype. The samples for snRNAseq were 2-4 mice per genotype. All attempts at replication were successful when a representative data set is provided.
Randomization In Morris water maze test, all mice from four genotypes were randomly assigned a new number. The hidden platform training and probe trails were conducted by new numerical order. The samples in all in vivo experiments (Electrophysiology, snRNAseq, IHC) were randomly allocated into experimental groups in an age-matching and sex-matching manner. For in vitro experiments, control and treatment groups were attributed randomly on wells and plates to account for the location effects.

Blinding
Experimenters were blinded of genotypes when performing image analysis and quantification for all IHC quantification experiments. Experimenters were blinded to group allocation during data collection and/or analysis for all of our in vivo experiments (Morris water maze test, electrophysiology, snRNAseq). For in vitro experiments, codes were assigned to different treatments, samples were collected, and

March 2021
analyzed and the samples were decoded at the end of experiment. For RNAseq experiments, the samples were assigned IDs and then processed blindly. We decoded the sample identities when we integrated the datasets.

Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. Secondaries used were anti-rabbit HRP (Calbiochem, 401393, 1:2000) or anti-mouse HRP (Calbiochem, 401253, 1:2000) For Immuno-gold labeling electron microscopy antibody against tau (Agilent Technologies, A0024, 1:1000) was used.

Validation
Each antibody was validated for the species (mouse or human) and application (immunohistochemistry, flow cytometry, immunoprecipitation) by the correspondent manufacturer. The validation studies can be found on the manufacturer's website. The usage was described in full detail the methods section of the manuscript. We further confirmed the STING antibody (D2P2F, Cell Signaling Technology) for use in immunohistochemistry by staining wild type and STING KO (Jackson Laboratory, Strain #: 017537). The confirmation data is not included in the manuscript.

Eukaryotic cell lines Policy information about cell lines and Sex and Gender in Research
Cell line source(s) BV2 cells were purchased from Banca Biologica e Cell Factory -IRCCS AOU San Martino -IST Genova. THP1-Dual™ Cells (Cat. number: thpd-nfis) and THP1-Dual™ KO-cGAS Cells (Cat. number: thpd-kocgas) were purchased from InvivoGen.

Authentication
Cell line authentication was performed by the supplier, but not independently authenticated in our lab. The supplier performed validation assays with Multiplex PCR: tested against human, rat, mouse primers. Confirmed as mouse with cytochrome c oxidase subunit I (cox I) primers.

Mycoplasma contamination
Cell lines were routinely tested for Mycoplasma contamination using a mycoplasma detection kit. No mycoplasma contamination was detected in the samples tested.

Commonly misidentified lines (See ICLAC register)
This manuscript does not involve experiments with any of the commonly misidentified lines.

Animals and other research organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in Research